CA
FTXH icon

Cetera Advisors’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Cetera Advisors’s Portfolio FTXH Stock Details FTXH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-20,053
Closed -$550K – 1677
2022
Q4 		$550K Buy
+20,053
New +$534K 0.01% 927

Other funds holding FTXH

RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
WFA
WMG Financial Advisors Knoxville, Tennessee $265M AUM 26.03% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return
NP
Nilsine Partners Greenwood Village, Colorado $1.45B AUM 47.06% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
KNW
Kesler Norman & Wride Ogden, Utah $631M AUM 27.63% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
PPWM
Paragon Private Wealth Management Lexington, Kentucky $320M AUM 23.48% 1-Year Est. Return

Cetera Advisors's FTXH Position: Q1 2023 in Review

Cetera Advisors sold out of First Trust Nasdaq Pharmaceuticals ETF (FTXH) in Q1 2023, closing a stake of 20,053 shares — an estimated $550K sold.

Cetera Advisors first reported a position in FTXH in Q4 2022 and held it in 1 quarter. The position peaked at $550K in Q4 2022. 31 funds tracked by Wall St. Rank hold FTXH as of Q1 2023.

  • Cetera Advisors reported no remaining First Trust Nasdaq Pharmaceuticals ETF position as of Q1 2023 after selling out during the quarter.
  • Cetera Advisors sold 20,053 First Trust Nasdaq Pharmaceuticals ETF shares in Q1 2023, an estimated $550K.
  • Cetera Advisors first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q4 2022 and held it in 1 quarter.
  • Cetera Advisors's First Trust Nasdaq Pharmaceuticals ETF position peaked at $550K in Q4 2022.
  • 31 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q1 2023.

Based on Cetera Advisors's 13F filing for Q1 2023, filed 15 May 2023.